Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Exclusive-Maker of Walmart, Amazon store-brand baby formulas sees shortages through rest of 2022

Published 05/13/2022, 01:26 PM
Updated 05/13/2022, 05:31 PM
© Reuters. FILE PHOTO: Birds are seen on the logo of generic drugmaker Perrigo Co outside their new factory in the city of Yeruham, in southern Israel March 2, 2016. REUTERS/Amir Cohen

By Jessica DiNapoli

NEW YORK (Reuters) -Perrigo Company PLC, which makes store-brand baby formulas for retailers, including Walmart (NYSE:WMT) Inc and Amazon.com Inc (NASDAQ:AMZN), expects shortages and heightened demand to last for the "balance of the year," Chief Executive Murray Kessler told Reuters in an interview.

The Biden administration this week has come under increasing pressure to address a baby formula shortage, which has roots in a February recall of some formulas by one of the nation's main manufacturers, Abbott Laboratories (NYSE:ABT).

"We have stepped up and are killing ourselves to do everything we can," Kessler said.

Perrigo's formula manufacturing facilities in Ohio and Vermont are now running at 115% of capacity, Kessler said.

At the request of the U.S. Food and Drug Administration, Perrigo is focusing on four items, the store-brand versions of Similac Pro Sensitive and Pro Advance and Enfamil Gentle Ease and Infant, Kessler said.

The company added that it is making other formulas as well. It also has a smaller business making some national formula brands, including Bobbie.

The closure of Abbott's infant-formula plant in Sturgis, Michigan, exacerbated national pandemic-related shortages, leading to empty shelves in big box stores and supermarkets and panicked parents. Abbott's brands include Similac formulas.

Perrigo is working with retailers including Walmart and Target Corp (NYSE:TGT) so they "get something each week," Kessler said. Retailers' allocations are based on an average of what the retailers received prior to "this crisis," he said.

Some retailers including CVS Health Corp (NYSE:CVS) and Target are rationing baby formula.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The White House on Thursday announced steps it is taking to alleviate the shortage, including permitting more imports. President Joe Biden said on Friday he expects more formula on shelves in weeks.

French food and beverage company Danone SA (OTC:DANOY), which also makes infant formulas, said the "unexpected Abbott Nutrition recall in February has led to a surge in demand in the U.S. market.

"We are in discussions with the U.S. authorities to see how we can support them in addressing their shortages.”

Of the total U.S. baby formula market, Perrigo makes up roughly 8%, Kessler said, adding that it has gained share as it has worked to satisfy the soaring demand.

Due to "massive inflation," Perrigo raised prices by about 3% in the first quarter, Kessler said.

The company has ordered materials to meet the heightened level of demand throughout the year, he said.

Bobbie, a European-style infant formula new to the market, saw its customer count double the first week after the recall of Abbott formulas, and it has continued to climb, CEO Laura Modi told Reuters.

Perrigo manufacturers Bobbie's formula, but can only meet about 50% of the company's demand, Modi said, leading it to stop taking new customers. Perrigo can meet 100% of Bobbie's current customer needs, she said.

Bobbie has about 70,000 customers.

Abbott closed its manufacturing facility in Michigan after complaints of bacterial contamination.

The FDA later cited five bacterial infections reported in babies given the company's formula, including two deaths. Abbott has said its plants are "not likely the source of infection" and is planning on re-opening the facility in the next two weeks.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest comments

Just another republican owned business goofing with Americans
Why do you make inciting comments under a fake name?
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.